{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:25:56Z","timestamp":1768562756891,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00393-019-0643-6","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T03:22:53Z","timestamp":1557804173000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Juvenile Dermatomyositis \u2013 was gibt es Neues?","Juvenile dermatomyositis\u2014what\u2019s new?"],"prefix":"10.1007","volume":"78","author":[{"given":"C.","family":"Hinze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"key":"643_CR1","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","volume":"141","author":"FA Aeschlimann","year":"2018","unstructured":"Aeschlimann FA, Fremond ML, Duffy D et\u00a0al (2018) A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain 141:e80","journal-title":"Brain"},{"key":"643_CR2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66:740\u2013749","journal-title":"Arthritis Rheumatol"},{"key":"643_CR3","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/rheumatology\/kew275","volume":"55","author":"R Aggarwal","year":"2016","unstructured":"Aggarwal R, Oddis CV, Goudeau D et\u00a0al (2016) Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxf) 55:1710","journal-title":"Rheumatology (Oxf)"},{"issue":"2","key":"643_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.arcped.2018.12.002","volume":"26","author":"B Bader-Meunier","year":"2019","unstructured":"Bader-Meunier B, Gitiaux C, Belot A et al (2019) French expert opinion for the management of juvenile dermatomyositis. Arch Pediatr 26(2):120. \nhttps:\/\/doi.org\/10.1016\/j.arcped.2018.12.002","journal-title":"Arch Pediatr"},{"key":"643_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","volume":"13","author":"EC Baechler","year":"2011","unstructured":"Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 13:249","journal-title":"Arthritis Res Ther"},{"key":"643_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N\u00a0Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"643_CR7","volume-title":"Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL)\/Anlage VI: Off-Label-Use Intraven\u00f6se Immunglobuline (IVIG) bei Polymyositis und bei Dermatomyositis","author":"Gemeinsamer Bundesausschuss","year":"2013","unstructured":"Gemeinsamer Bundesausschuss (2013) Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL)\/Anlage VI: Off-Label-Use Intraven\u00f6se Immunglobuline (IVIG) bei Polymyositis und bei Dermatomyositis (BAnz AT 09.07.2013 B1)"},{"key":"643_CR8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00393-006-0109-5","volume":"65","author":"F Dressler","year":"2006","unstructured":"Dressler F, Huppertz HI (2006) Juvenile dermatomyositis. Z\u00a0Rheumatol 65:587\u2013590 (592\u2013584)","journal-title":"Z Rheumatol"},{"key":"643_CR9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"FB Enders","year":"2017","unstructured":"Enders FB, Bader-Meunier B, Baildam E et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329\u2013340","journal-title":"Ann Rheum Dis"},{"key":"643_CR10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K et al (2012) Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513\u2013522","journal-title":"Arthritis Rheum"},{"key":"643_CR11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a\u00a0type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256\u2013262","journal-title":"Ann Rheum Dis"},{"key":"643_CR12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-018-0257-6","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Oommen PT, Dressler F et al (2018) Development of practice and consensus-based strategies including a\u00a0treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol Online\u00a0J 16:40","journal-title":"Pediatr Rheumatol Online J"},{"key":"643_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-018-0256-7","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Speth F, Oommen PT et\u00a0al (2018) Current management of juvenile dermatomyositis in Germany and Austria: An online survey of pediatric rheumatologists and pediatric neurologists. Pediatr Rheumatol Online\u00a0J 16:38","journal-title":"Pediatr Rheumatol Online J"},{"key":"643_CR14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","volume":"77","author":"J Hornig","year":"2018","unstructured":"Hornig J, Weinhage T, Schmidt LH et\u00a0al (2018) Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z\u00a0Rheumatol 77:952\u2013957","journal-title":"Z Rheumatol"},{"key":"643_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","volume":"44","author":"AM Huber","year":"2017","unstructured":"Huber AM, Kim S, Reed AM et\u00a0al (2017) Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J\u00a0Rheumatol 44:110\u2013116","journal-title":"J Rheumatol"},{"key":"643_CR16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","volume":"64","author":"AM Huber","year":"2012","unstructured":"Huber AM, Robinson AB, Reed AM et\u00a0al (2012) Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res 64:546\u2013553","journal-title":"Arthritis Care Res"},{"key":"643_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","volume":"15","author":"S Kim","year":"2017","unstructured":"Kim S, Kahn P, Robinson AB et\u00a0al (2017) Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online\u00a0J 15:1","journal-title":"Pediatr Rheumatol Online J"},{"key":"643_CR18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"T Kishi","year":"2017","unstructured":"Kishi T, Rider LG, Pak K et al (2017) Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res 69:1088\u20131094","journal-title":"Arthritis Care Res"},{"key":"643_CR19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I et\u00a0al (2015) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxf) 54:784\u2013791","journal-title":"Rheumatology (Oxf)"},{"key":"643_CR20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Suarez-Calvet X, Toquet S et al (2018) JAK inhibitor improves type I interferon induced damage: Proof of concept in dermatomyositis. Brain 141:1609\u20131621","journal-title":"Brain"},{"key":"643_CR21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","volume":"72","author":"D Lazarevic","year":"2013","unstructured":"Lazarevic D, Pistorio A, Palmisani E et\u00a0al (2013) The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 72:686\u2013693","journal-title":"Ann Rheum Dis"},{"key":"643_CR22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","volume":"56","author":"WC Liang","year":"2017","unstructured":"Liang WC, Uruha A, Suzuki S et al (2017) Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxf) 56:287\u2013293","journal-title":"Rheumatology (Oxf)"},{"key":"643_CR23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker JB, Vencovsky J, Wang G et\u00a0al (2018) The EuroMyositis Registry: An international collaborative tool to facilitate myositis research. Ann Rheum Dis 77:30\u201339","journal-title":"Ann Rheum Dis"},{"key":"643_CR24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M et\u00a0al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964","journal-title":"Ann Rheum Dis"},{"key":"643_CR25","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/acr.22088","volume":"65","author":"G Mamyrova","year":"2013","unstructured":"Mamyrova G, Katz JD, Jones RV et\u00a0al (2013) Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res 65:1969\u20131975","journal-title":"Arthritis Care Res"},{"key":"643_CR26","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/kex162","volume":"56","author":"G Mamyrova","year":"2017","unstructured":"Mamyrova G, Rider LG, Ehrlich A et\u00a0al (2017) Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology (Oxf) 56:1342\u20131347","journal-title":"Rheumatology (Oxf)"},{"key":"643_CR27","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.38137","volume":"65","author":"FW Miller","year":"2013","unstructured":"Miller FW, Cooper RG, Vencovsky J et al (2013) Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 65:3239\u20133247","journal-title":"Arthritis Rheum"},{"key":"643_CR28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A\u00a0randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"issue":"3","key":"643_CR29","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1093\/brain\/awz005","volume":"142","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Hong Y, Omoyinmi E et\u00a0al (2019) Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain 142(3):e8. \nhttps:\/\/doi.org\/10.1093\/brain\/awz005","journal-title":"Brain"},{"key":"643_CR30","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","volume":"9","author":"CJM Piper","year":"2018","unstructured":"Piper CJM, Wilkinson MGL, Deakin CT et\u00a0al (2018) CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-alpha. Front Immunol 9:1372. \nhttps:\/\/doi.org\/10.3389\/fimmu.2018.01372","journal-title":"Front Immunol"},{"key":"643_CR31","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed AM, Peterson E, Bilgic H et\u00a0al (2012) Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 64:4078\u20134086","journal-title":"Arthritis Rheum"},{"key":"643_CR32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","volume":"37","author":"GI Rice","year":"2017","unstructured":"Rice GI, Melki I, Fremond ML et\u00a0al (2017) Assessment of type I interferon signaling in pediatric inflammatory disease. J\u00a0Clin Immunol 37:123\u2013132","journal-title":"J Clin Immunol"},{"key":"643_CR33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"LG Rider","year":"2017","unstructured":"Rider LG, Aggarwal R, Pistorio A et\u00a0al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 69:911\u2013923","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 11","key":"643_CR34","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 63(Suppl 11):S118\u2013S157 (Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI))","journal-title":"Arthritis Care Res"},{"key":"643_CR35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.40395","volume":"70","author":"S Ringold","year":"2018","unstructured":"Ringold S, Nigrovic PA, Feldman BM et\u00a0al (2018) The childhood arthritis and rheumatology research alliance consensus treatment plans: Toward comparative effectiveness in the pediatric rheumatic diseases. Arthritis Rheumatol 70:669\u2013678","journal-title":"Arthritis Rheumatol"},{"key":"643_CR36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","volume":"214","author":"MP Rodero","year":"2017","unstructured":"Rodero MP, Decalf J, Bondet V et\u00a0al (2017) Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J\u00a0Exp Med 214:1547\u20131555","journal-title":"J Exp Med"},{"key":"643_CR37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S et al (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A\u00a0randomised trial. Lancet 387:671\u2013678","journal-title":"Lancet"},{"key":"643_CR38","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GA Montealegre Sanchez","year":"2018","unstructured":"Montealegre Sanchez GA, Reinhardt A, Ramsey S et\u00a0al (2018) JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J\u00a0Clin Invest 128:3041\u20133052","journal-title":"J Clin Invest"},{"key":"643_CR39","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","volume":"65","author":"M Shah","year":"2013","unstructured":"Shah M, Targoff IN, Rice MM et\u00a0al (2013) Brief report: Ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 65:1934\u20131941","journal-title":"Arthritis Rheum"},{"key":"643_CR40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Bitton A, Katz JN et\u00a0al (2014) Review: Treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis? Arthritis Rheumatol 66:775\u2013782","journal-title":"Arthritis Rheumatol"},{"key":"643_CR41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","volume":"44","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Betteridge ZE, Simou S et al (2017) Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a\u00a0rare but clinically important subset of patients. J\u00a0Rheumatol 44:488\u2013492","journal-title":"J Rheumatol"},{"key":"643_CR42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Simou S, Shaddick G et al (2017) Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a\u00a0large UK cohort. J\u00a0Autoimmun 84:55\u201364","journal-title":"J Autoimmun"},{"key":"643_CR43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/s-0038-1675731","volume":"38","author":"K Tenbrock","year":"2018","unstructured":"Tenbrock K, Foell D, Minden K et al (2018) Handlungs- und Therapie-Protokolle in der Kinder-Rheumatologie. Arthritis Rheuma 38:368","journal-title":"Arthritis Rheuma"},{"key":"643_CR44","first-page":"787","volume":"56","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou E, Pinal-Fernandez I, Lloyd TE et al (2017) More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxf) 56:787\u2013794","journal-title":"Rheumatology (Oxf)"},{"key":"643_CR45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","volume":"77","author":"RM Yeker","year":"2018","unstructured":"Yeker RM, Pinal-Fernandez I, Kishi T et al (2018) Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Ann Rheum Dis 77:714\u2013719","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0643-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-0643-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0643-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T23:21:57Z","timestamp":1589239317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-0643-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-0643-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]},"assertion":[{"value":"13 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Hinze hat f\u00fcr die Teilnahme an Advisory Boards Honorare von Novartis und von Shire erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von dem Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}